Analysts expect Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) to report sales of $3.95 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Aurinia Pharmaceuticals’ earnings, with the highest sales estimate coming in at $7.10 million and the lowest estimate coming in at $430,000.00. The firm is expected to report its next quarterly earnings report on Thursday, May 13th.
According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year sales of $67.96 million for the current fiscal year, with estimates ranging from $48.79 million to $87.80 million. For the next financial year, analysts expect that the company will post sales of $220.98 million, with estimates ranging from $155.21 million to $269.26 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Tuesday, February 23rd. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.26. Aurinia Pharmaceuticals had a negative return on equity of 36.98% and a negative net margin of 173,992.23%.
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in Aurinia Pharmaceuticals by 4.3% during the 3rd quarter. BlackRock Inc. now owns 1,226,284 shares of the biotechnology company’s stock valued at $18,063,000 after purchasing an additional 50,458 shares during the period. Morgan Stanley boosted its holdings in shares of Aurinia Pharmaceuticals by 550.8% during the fourth quarter. Morgan Stanley now owns 812,324 shares of the biotechnology company’s stock valued at $11,234,000 after acquiring an additional 687,500 shares during the period. Hudson Bay Capital Management LP grew its position in shares of Aurinia Pharmaceuticals by 26.1% during the fourth quarter. Hudson Bay Capital Management LP now owns 700,000 shares of the biotechnology company’s stock worth $9,681,000 after acquiring an additional 145,000 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Aurinia Pharmaceuticals by 76.2% in the 4th quarter. Wells Fargo & Company MN now owns 666,597 shares of the biotechnology company’s stock worth $9,219,000 after acquiring an additional 288,250 shares during the period. Finally, Kestra Private Wealth Services LLC increased its holdings in shares of Aurinia Pharmaceuticals by 35.3% in the 4th quarter. Kestra Private Wealth Services LLC now owns 406,000 shares of the biotechnology company’s stock worth $5,668,000 after acquiring an additional 106,000 shares during the period. Institutional investors and hedge funds own 51.21% of the company’s stock.
Shares of NASDAQ:AUPH opened at $12.65 on Thursday. The firm has a market cap of $1.61 billion, a PE ratio of -8.61 and a beta of 0.87. The company has a fifty day simple moving average of $13.75 and a 200 day simple moving average of $14.46. Aurinia Pharmaceuticals has a 12-month low of $12.01 and a 12-month high of $20.50.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.